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Although tumours express antigens recognized by cytotoxic T
lymphocytes (CTL), they are mostly non-immunogenic, as they
cannot activate T cells or maintain an activated T cell response
(Speiser et al, 1997). To increase their immunogenicity, superanti-
gens, haptens, foreign antigens derived from viruses, or allogeneic
MHC genes have been introduced into tumours (Lindenmann and
Klein, 1967; Fearon et al, 1988; Plautz et al, 1993; Stopeck et al,
1997; Berd et al, 1998; Dow et al, 1998; Heo et al, 1998). These
modified tumours enhance immune response against wild-type
tumour cells and clinical responses have been recorded. The iden-
tification of specific tumour antigens has led to the hypothesis that
failure of the immune system to eliminate tumours resulted from
an absence of a costimulatory signal provided by tumour cells
which is thought to be required for full activation of T cells
(Janeway and Bottomly, 1994; Chen, 1998). Various groups have
shown that tumour cells transfected to express immunostimulatory
cytokines are able to induce immune responses leading to rejection
in experimental animal models (Fearon et al, 1990; Schmidt-Wolf
and Schmidt Wolf, 1995; Tartour and Fridman, 1998). In some
cases, vaccination with cytokine-producing tumour cells protected
against subsequent challenge with an otherwise lethal dose of
wild-type tumour and eliminated pre-existing cancer deposits
(Gansbacher et al, 1990; Dranoff et al, 1993; Maass et al, 1995;
Zatloukal et al, 1995; Clary et al, 1997). Unfortunately, in man, the
development of autologous tumour vaccines has proven to be
more complex due to the requirement for establishing tumour cell
lines for each patient and the need for efficient ex vivo transfec-
tion. Golumbek et al first showed that paracrine delivery of a
cytokine at the tumour site could elicit an immune response
similar to that of cytokine-modified tumour cells. The authors
evaluated the ability of GM-CSF-containing microspheres to act
as an adjuvant when mixed with irradiated tumour cells prior to
immunization and showed that these preparations produced
vaccine effects equivalent to those of GM-CSF-transduced tumour
cells (Golumbek et al, 1993) Similarly, vaccines composed of
irradiated melanoma cells admixed with liposomal IL-2 are as
effective as IL-2 gene modified tumour cells in evoking protective
immunity against tumour cells (Koppenhagen et al, 1998).
Interestingly, large amounts of free GM-CSF or IL-2 in these same
tumour models were ineffective suggesting that sustained release
of cytokines at the tumour site was required to achieve the anti-
tumour effect (Golumbek et al, 1993; Pardoll, 1995; Koppenhagen
et al, 1998). Other successful strategies used for paracrine
cytokine delivery at the tumour site have included direct in vivo
administration of recombinant viral vectors allowing effective in
situ expression of the cytokine gene in the tumour cells or the mix
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Summary Various studies have emphasized an immunodepression state observed at the tumour site. To reverse this defect and based upon
animal studies, we initiated a phase I clinical trial of gene therapy in which various doses of xenogeneic monkey fibroblasts (Vero cells)
genetically engineered to produce human IL-2 were administered intratumorally in 8 patients with metastatic solid tumours. No severe
adverse effect was observed in the 8 patients analysed during this clinical trial even in the highest dose (5 ¥ 107 cells) group. This absence
of toxicity seems to be associated with rapid elimination of Vero-IL-2 cells from the organism. Indeed, exogenous IL-2 mRNA could no longer
be detected in the peripheral whole blood 48 hours after Vero-IL-2 cell administration. In addition, we did not find any expression of
exogenous IL-2 mRNA in post-therapeutic lesions removed 29 days after the start of therapy. A major finding of this trial concerns the two
histological responses of two treated subcutaneous nodules not associated with an apparent clinical response. The relationship between local
treatment and tumour regression was supported by replacement of tumour cells by inflammatory cells in regressing lesions and marked
induction  of
T and natural killer cell derived cytokines (IL-2, IL-4, IFNg …) in post-therapeutic lesions analysed 28 days after the start of Vero-IL-2
administration. Gene therapy using xenogeneic cells as vehicle may therefore present certain advantages over other vectors, such as its
complete absence of toxicity. Furthermore, the in vivo biological effect of immunostimulatory genes, i.e IL-2-, may be potentiated by the
xenogeneic rejection reaction. © 2000 Cancer Research Campaign http://www.bjcancer.com
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of cytokine-secreting fibroblasts with tumour cells (Bubenik et al,
1988; Haddada et al, 1993; Addison et al, 1995; Cordier et al,
1995). Various groups have shown that immunization with IL-2 or
IL-12-secreting autologous or allogeneic fibroblasts associated
with tumour cells induced anti-tumour immunity and was able to
cure established tumours in animals (Tahara et al, 1994; Fakhrai et
al, 1995; Glick et al, 1997). In man, in a phase I clinical trial, in
which autologous tumour cells plus interleukin-2 gene transfected
allogeneic fibroblasts were administered to cancer patients, an
enhancement of specific anti-tumour T cell responses was
observed (Veelken et al, 1997). Roth et al also showed that xeno-
geneic cells engineered to secrete IL-2 induced protection against
tumour development (Roth et al, 1992). In the light of these
results, Mehtali et al selected the simian fibroblast Vero cell line as
a cell vector for IL-2 production, due to its excellent characteriza-
tion and safety records established during the pharmaceutical
production of human poliovirus vaccine (Leroy et al, 1998). The
use of the same IL-2-producing cell line would allow standardiza-
tion of cytokine production from one patient to another. It also
circumvented the risk of long-term persistence in the host of auto-
logous tumour cells or fibroblasts transduced with IL-2 cDNA.
Indeed, histoincompatible cells were rejected by the host but, in
previous studies, it seemed that the half-life of the IL-2 molecule
secreted by these cells was longer than that observed after
injection of free recombinant IL-2, which suggests a possible
sustained production of cytokine released by histoincompatible
cells (Mir et al, 1995).
When a mixture of thyroid medullary carcinoma cells and
IL-2-secreting Vero cells was implanted in rats, tumour growth
was inhibited as a function of the number of interleukin-secreting
Vero cells in the inoculum (Cressent et al, 1995).
Cats with spontaneously arising fibrosarcoma and dogs with
buccal melanoma, when treated by tumour surgery, radiotherapy
and repeated local injections of xenogeneic cells secreting high
levels of IL-2, relapsed less frequently than control animals treated
by surgery and radiotherapy alone. In contrast, all cats treated with
surgery and irradiation and then injected locally with either
recombinant IL-2 or unmodified Vero cells quickly relapsed
(Quintin-Colonna et al, 1996). These encouraging data prompted
us to conduct a phase I clinical trial, to evaluate the biological and
clinical effects of intratumour administration of Vero-IL-2 cells in
cancer patients with accessible metastatic tumours.
PATIENTS AND METHODS
Patients
Patients with accessible subcutaneous metastases were included in
this phase I study. Eligibility criteria also required that patients had
not received chemotherapy, radiotherapy or immunotherapy for at
least 4 weeks before starting the study and had a predicted survival
<3 months and a Karnofsky status index < 70. Other patient
characteristics are listed in Table 1.
This study was approved by a regional ethics committee and
patients were included after giving their written informed consent.
Toxicity and response evaluation
A complete history, physical examination, determination of
performance status, full blood count, serum biochemistry and
urinalysis were obtained before admission into the study for each
patient. Serum electrolytes, liver and renal function and blood
counts were regularly monitored during each course.
Toxicities were graded on a scale of 0–4 using the Common
Toxicity Criteria of the United States National Cancer Institute.
Local clinical response was assessed after each cycle by
measuring the largest diameter and the largest perpendicular
portion of the nodules in which Vero cells were administered.
Tumour evaluation at other metastatic sites included physical
examination, chest radiographs and/or computed tomography and
ultrasound.
Preparation and characterization of Vero-IL-2 cells
The monkey Vero fibroblast cell lines were provided by ATCC-
CCI81 (Rockville, MD, USA). They were transfected with
pTG5324 plasmid containing the human IL-2 cDNA using the
calcium phosphate coprecipitation technique and were cultured in
DMEM medium with 10% fetal calf serum in the presence of
6 µ g ml–1 of puromycin (Sigma, Saint Quentin Fallavier, France),
as previously described (Quintin-Colonna et al, 1996). Resistant
clones were selected and stored in liquid nitrogen in freezing
medium (DMEM, 2 mM L-glutamine, 1% non essential amino
acids, 0.1% HSA, 5% DMSO) in ready-to-use aliquots of 1 ml
containing 3 × 107 cells. Before administration to the patient, the
Table 1 Patient characteristics
Age Prior Tumour type Number of Vero Local response Survival
treatment cells (months)
administered
Patients
1 50 S,R,C,H Breast adenocarcinoma 5.105 NR >38
2 57 S,R,C,H Breast adenocarcinoma 5.105 NR 5
3 52 S,R,C,H Breast adenocarcinoma 5.105 NR 27
4 57 S,R,C,H Breast adenocarcinoma 5.106 HR >34
5 72 S,R,C,H Breast adenocarcinoma 5.106 NR 9
6 65 S,R,C,H Breast adenocarcinoma 5.106 NR >25
7 39 S,R,C,H Breast adenocarcinoma 5.107 NR >24
8 59 S,C. Colorectal carcinoma 5.107 HR 12
Abbreviations: S: surgery; R: radiation therapy; C: chemotherapy; H: hormone therapy; NR: no clinical response; HR: local histological response without clinical
response.number of viable cells was determined by Trypan blue dye exclu-
sion. After thawing, the median viability of cells was 86% (range:
70 to 95%). IL-2 production of Vero-IL-2 cells from each batch
was also measured using enzyme-linked immunosorbent assay
(ELISA) kits purchased from R&D systems (Minneapolis, USA).
The median amount of IL-2 produced by injected cells was 130 ng
106 cells–1 24 h ml–1 (range: 45–245).
Study design
Three dose levels of Vero-cells were administered: 5 × 105, 5 × 106
and 5 × 107 cells. Cells were injected into subcutaneous metastatic
nodules, three times at 7-day intervals. Three patients were
recruited in the first and second dose levels. Only two patients
were included in the third dose level.
Collection of samples
Biopsies of subcutaneous nodules were obtained before and 29
days after intratumour Vero-IL-2 administration. Tissues were
divided in two equal parts: one portion was fixed in formalin for
histological examination, and the other was snap-frozen in liquid
nitrogen and stored at –70° C for RNA extraction. Vero-IL-2 cells
were injected into a subcutaneous nodule adjacent to that chosen
for pretreatment biopsy.
Plasma for cytokine assay and whole blood for vector detection
were collected from all patients before treatment and on days 3, 8,
10, 15, 17, 22 after the first administration of Vero IL-2 cells.
Assays
IL-2 and IL-4 serum levels were determined by commercially
available ELISA kits from R&D (Minneapolis, MN). Soluble IL-2
receptor was measured using ELISA kits from Immunotech
(Marseille, France). IFNγ was assayed using an ELISA kit from
Diaclone (Besançon, France).
Cytokine mRNA analysis in tumour biopsies
Total cellular RNA was extracted from peripheral whole blood
using the RNA-zol B method. Two µ g of total cellular RNA were
mixed with oligo-dT primers to synthesize cDNA (First strand
cDNA synthesis kit; Boehringer-Mannheim, Germany) according
to the manufacturer’s protocol.
PCR was performed as previously described (Tartour et al,
1998). Table 2 gives the sequence of cytokine primers used in this
study and the design of the two pairs of IL-2 primers chosen to
discriminate between endogenous IL-2 and exogenous IL-2.
The size of the PCR products will allow us to discriminate
between endogenous and exogenous IL-2 mRNA.
Histochemical analysis
For every patient, paraffin-embedded sections derived from
pretreatment and post-treatment biopsies were stained with
haematoxylin and eosin. All histological sections were reviewed
by two pathologists.
RESULTS
Clinical findings
Toxicity
The treatment and injection procedures were well tolerated. No
laboratory abnormality and no sign of organ toxicity related to
treatment were recorded in any of the 8 patients analysed. No sign
related to the IL-2 toxicity previously observed when administered
systemically (hypotension, renal dysfunction, weight gain, haema-
tological disorder, nausea) was recorded.
During the course of treatment, patient 2 developed cholestasis
secondary to disease progression with bile duct compression.
Clinical response and follow-up
No patient exhibited any clinical regression of the treated sub-
cutaneous nodules. Patients 3 and 4 developed local erythema and
inflammation at the site of the injected nodules 48 hours after the
start of therapy during the first cycle for patient 3 and the third
cycle for patient 4. This local phenomenon resolved sponta-
neously. Patients 4 and 7 were considered to present stable disease
3 months after the start of therapy, while the other patients
clinically progressed. Survival analysis is described for each
patient in Table 1.
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Table 2 Sequences of 5′ and 3′ primers of 7 target genes
mRNA species Size of
PCR products
β actin 5′ TCG TCG ACA ACG GCT CCG GCA TGT GC
3′ TTCTGCAGGGAGGAGCTGGAAGCAGC 688
IFNγ 5′ GGT TCT CTT GGC TGT TAC TGC C
3′ GTT GGA CAT TCA AGT CAG TTA CCG A 340
IL-2 End 5′ ACA TGC CCA AGA AGG CCA C
3′ AGT GTT GAG ATG ATG CTT TG 265
IL-2 TG 5′ TCT GAT AGG CAG CCT GCA CC
3′ TCC TAC AGC TCC TGG GCA ACG 595
CD3 5′ TGT CTG AGA GCA GTG TTC CCA C
3′ CCA GGC TGA TAG TTC GGT GAC C 220
IL4 5′ GTA AGC TTC TCC TGA TAA ACT AAT TGC CTC AC
IL4 3′ AAG AAT TCC AAC GTA CTC TGG TTG GCT TCC TT 470
IL10 5′ AGT CTG AGA ACA GCT GCA CCC AC
IL10 3′ CAC TCA TGG CTT TGT AGA TGC C 335Laboratory findings
Vector detection in peripheral whole blood and tumour
specimens
We designed primers to discriminate between endogenous IL-2
mRNA and exogenous IL-2 mRNA derived from Vero-IL-2 cells.
Figure 1 shows that IL-2 TG primers amplified cDNA prepared
from Vero-cell mRNA, but not from activated peripheral whole
blood (PBMC) mRNA, whereas IL-2 end primers detected mRNA
derived from both Vero-IL-2 cells and activated PBMC. IL-2 TG
primers were unable to detect exogenous IL-2 mRNA – a surro-
gate marker of the persistence of Vero-IL-2 cells – in peripheral
whole blood of any of the patients. Samples were collected before
each cycle and 48 and 96 hours after Vero-IL-2 cell injection in
tumour cells. Using the same technique, we did not find any
expression of exogenous IL-2 mRNA derived from Vero-cells in
post-treatment tumour biopsies removed 29 days after the start of
therapy. However, we could not accurately assess the half life of
the Vero cells at the tumour site.
Histochemical analysis of pre and post-treatment biopsies
Post-treatment biopsies of patients 4 and 8 showed complete
disappearance of tumour cells, which were replaced by granuloma
and inflammatory cells (Figure 2A, B and data not shown). This
Cancer gene therapy with xenogeneic IL-2 cells 1457
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Figure 1 Design of primers to discriminate endogenous and exogenous
IL-2 mRNA. RT-PCR was performed on mRNA extracted from Vero-IL-2 cells
or PHA-activated peripheral blood mononuclear cells (PBMC). Two couples
of primers were used: IL-2 TG, which specifically amplifies the sequence of
IL-2 cDNA included in the pTG5324 plasmid, whereas IL-2 end detected both
exogenous and endogenous IL-2. Amplified products were loaded onto 2%
agarose gel and stained with ethidium bromide. Negative controls in which
H2O replaced cDNA were also included.
Figure 2 Histological analysis of pre- and post-treatment nodules of patient 4. (Magnification × 40). Paraffin-embedded sections were stained with
haematoxylin and eosin. (A) Pre-treatment biopsies: adenocarcinoma cells were encapsulated and surrounded by infiltrating cells. (B) Post-treatment biopsies
performed 29 days after Vero-IL-2 cells administration. Complete disappearance of tumour cells which were replaced by granuloma and inflammatory cells.local histological response of treated nodules was therefore not
expected on the basis of clinical findings.
To assess the possible relationship between this histological
response and Vero-IL-2 cell administration, one non-treated
nodule was removed in patients 4 and 8. Metastatic tumour cells
were found in all biopsies analysed with no significant inflamma-
tory reaction. These results support the hypothesis that the local
clinical anti-tumour response was related to Vero-IL-2 therapy.
They also suggest that the host reaction remained localized to the
site of Vero-IL-2 cell injection.
Cytokine determination in serum and biopsies of patients
IL-2 has been shown to induce a cascade of cytokines in vivo
which could reflect its in vivo activity (Gemlo et al, 1988;
Schaafsma et al, 1991; Tartour et al, 1992). Therefore, to address a
possible systemic effect of intra-tumour administration of Vero
cells, cytokines were measured in the plasma of cancer patients
before and after local therapy. We did not find an increase of serum
IL-2, IL-4 and IFN-γ levels for any patient on samples collected
before treatment and on days 3, 8, 10, 15, 17 and 22 after adminis-
tration of Vero cells (Figure 3 and data not shown). Previous
studies reported that the presence of IL-2 in the systemic circula-
tion is often very transient, even after i.v. IL-2 administration and
that the increase of serum soluble IL-2 receptor levels is more
stable and easier to monitor (Lotze et al, 1987; Konrad et al, 1990).
We, therefore, also measured serum sIL-2R levels in the patients.
We did not find any significant induction of sIL-2R levels after
local injection of Vero-IL-2 cells, which supports the absence of a
marked systemic release of IL-2 from the tumour site of injection.
These results are in line with those reported above concerning the
absence of exogenous IL-2 mRNA detected in the circulation of
treated patients.
Cytokines are considered to exert their biological effect via a
paracrine mechanism (Pardoll, 1995). To assess a possible local
in vivo biological effect of this cell therapy, we established a
cytokine mRNA profile in biopsies taken from patients before and
1 month after Vero-IL-2 cell injection. For this semi-quantitative
analysis, all results were normalized to β actin gene expression.
Marked induction of IFNγ , IL-2 and IL-4 mRNA was demon-
strated in post-treatment biopsies of patients 1, 3, 4, 6, and 8
(Figures 4, 5 and data not shown). Two of these patients (4 and 8)
exhibited a histological response of the treated nodules.
Patient 3 developed local erythema 48 hours after the first injec-
tion of Vero-IL-2 cells. It should be emphasized that, in contrast
with the rather specific T and NK cell-derived cytokines (IL-2,
IL-4, IFNγ ), IL-10 mRNA was not found to be increased in post-
treatment biopsies of patient 8 (Figure 4). In an attempt to relate
this local cytokine activation to treatment, treated and non-treated
nodules were both removed 29 days after therapy in patient 6. The
activation state was only observed in the treated nodule (Figure 5).
In some patients (1, 6, 8), this increase was not associated with a
parallel increase of CD3 mRNA, a T cell marker (Figures 4, 5 and
data not shown).
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Figure 3 Cytokine detection in plasma of patient 1. Soluble IL-2 receptor
(sIL-2-R), IL-2, IL-4 and IFNγ were measured in the plasma of patient 1
before and at different times after intratumour Vero-IL-2 cell administration.
sIL-2R scale (pM) is shown on the right of the figure, whereas IL-2, IL4 and
IFNγ scale (pg ml–1) is shown on the left of the figure. The results shown are
representative of the profile observed in the series of patients. IL-2, IL-4 and
IFNγ levels were below the limit of detection.
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Figure 4 Cytokine mRNA determination in pre- and post-treatment biopsies
derived from patients with histological response (patients 4 and 8). mRNA
derived from pre-treatment nodules (d0) and post-treatment nodules (d29)
were reverse transcribed into cDNA. A PCR was then performed using
different primers specific for CD3, IFNγ , IL-2 and IL-4 cDNA. For patient 8,
specific primers for IL-10 were also introduced. Amplified products were
loaded onto 2% agarose gel and stained with ethidium bromide. All results
were normalized to β actin gene expression. Negative controls in which H2O
replaced cDNA were also included.
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Figure 5 Cytokine mRNA determination in Vero-IL-2 cell treated and
non-treated nodules of patient 6. mRNA derived from pre-treatment nodules
(d0) and post-treatment treated (T) or non-treated (NT) nodules (d29) were
reverse transcribed into cDNA. A PCR was then performed using different
primers specific for CD3, IFNγ , IL-2 and IL-4 cDNA. Amplified products were
loaded onto 2% agarose gel and stained with ethidium bromide. All results
were normalized to β actin gene expression.DISCUSSION
No severe adverse effect was observed in the 8 patients analysed
during this phase I clinical trial. The maximal tolerated dose
(MTD) was therefore not reached even in the higher dose group.
This absence of toxicity seems to be associated with rapid elimina-
tion of Vero-IL-2 cells from the body as exogenous IL-2 mRNA
could no longer be detected in peripheral whole blood collected as
early as 48 hours after Vero-IL-2 cell administration and in the
patients’ post-treatment biopsies.
These results are in line with previous studies in which a
positive transgene DNA signal in the biopsies was demonstrated
only 1 hour after intra-tumour injection of Vero-IL-2 cells in cats
(Quintin-Colonna et al, 1996). In a similar phase I clinical trial,
Rochlitz also did not find any expression of exogenous mRNA 24
hours after local cell injection (Rochlitz et al, 1999). As expected,
these data suggest that xenogenic cells are rapidly rejected by the
host.
One major finding of this trial concerns the histological
response without clinical response of two treated subcutaneous
nodules in two patients. The relationship between local treatment
and tumour regression was reinforced by the replacement of
tumour cells by inflammatory cells in regressing lesions.
Furthermore, different non-treated control nodules collected at the
same time period after therapy in these two patients did not exhibit
any significant inflammatory reaction and tumour cells were
present in all cases.
This discrepancy between clinical and histological results was
also reported in a series of melanoma patients treated by IFNα and
high-dose IL-2, as in 11 patients, residual tumour lesions were
resected and histology revealed almost complete tumour regres-
sion in 6 patients (Keilholz et al, 1994). Clinical evaluation during
immunotherapy protocols may therefore underestimate the anti-
tumour effect of these biological response modifiers.
This peculiar histological response was associated with marked
induction of T and NK cell-derived cytokines (IL-2, IL-4, IFNγ …)
in post-treatment lesions. This intra-tumour cytokine induction
was also observed in 3 non-responder patients. This finding is
reminiscent of previous results, in which activation of immune
system was a necessary but not sufficient condition to achieve
clinical response (Dorval et al, 1992; Tartour et al, 1992). In order
to correlate this activation state to treatment, we showed that
no marked induction of IL-2, IL-4 or IFNγ mRNA could be
demonstrated in non-treated control biopsies (Figure 5).
Although the antitumour effect of IL-2 and IFNγ has been
clearly established, the clinical significance of IL-4 is more
controversial. Pioneer studies in murine models clearly associated
the increase of IL-4 mRNA in the spleen of tumour-bearing mice
with tumour progression (Ghosch et al, 1995). In man, an increase
of TH2 cytokines (IL-4, IL-10) with a defect of TH1 cytokine
(IL-2, IFNγ ) at the tumour site has been reported in several models
(Wang et al, 1995; Chouaib et al, 1997; Tartour et al, 1998). In
some circumstances immunotherapy can correct this defect
(Vowels et al, 1994). On the basis of these observations,
IL-4 was therefore considered to be a marker of poor prognosis.
However, other studies in murine models showed that tumours
transfected with IL-4 cDNA were rejected and could protect
against a challenge with parental tumour (Tepper et al, 1989;
Golumbek et al, 1991). In vivo delivery of interleukin-4 by a
recombinant vaccinia virus prevented tumour development in
mice (Elkins et al, 1994). Recently, Schuler et al demonstrated that
IL-4 knock out mice were severely impaired to develop tumour
immunity (Schuler et al, 1999). This lack of tumour immunity in
IL-4 knock out mice was associated with reduced IFNγ production
and undetectable CTL activity. The IL-4 mRNA induction
observed in tumour biopsies after Vero cells administration may
therefore be associated with a clinical benefit.
The design of the protocol did not allow us to assess the respec-
tive roles of xenogenic cells and IL-2. However, in murine models,
histoincompatible cells not secreting IL-2 only display marginal
effects on tumour growth (Roth et al, 1992). Cats treated by
surgery, radiotherapy and repeated local injections of xeno-
geneic Vero cells not secreting IL-2 relapsed more frequently
than when Vero cells secreting high levels of IL-2 were used
(Quintin-Colonna et al, 1996)
The rationale of this immunotherapy approach is discussed by
several groups, as it has been shown that local IL-2 production is
most effective when the helper cytokine is secreted by the tumour
cell (Tsai et al, 1993). The use of allogeneic fibroblasts or allo-
geneic tumour cells modified to secrete cytokines has been found
to be less potent to induce an antitumour response than when
syngenic fibroblasts or autologous tumour cells transfected with
IL-2 were used as a vaccine (Aruga et al, 1997; Bowman et al,
1998). Allogeneic or xenogeneic cells engineered to secrete IL-2
induce protection against tumour development via stimulation of
IL-2-dependent natural killer activity, whereas syngenic tumour
cells transfected with IL-2 confer protection by stimulating
tumour-specific CTL (Roth et al, 1992; Tsai et al, 1993). This may
explain the absence of clinical or immunological effects observed
at sites distant from the injection of Vero IL-2 cells.
Melanoma and renal cell carcinoma are usually considered to be
the main tumours sensitive to immunotherapy (Mukherji and
Chakraborty, 1995). In this trial and a similar trial reported by
Rochlitz et al (1999), colorectal carcinoma, sarcoma and breast
carcinoma tumour cells appeared to be sensitive to this type of
immunotherapy. The safety of this treatment procedure associated
with these promising data prompted us to initiate a multicentre
phase II trial.
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